MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

Home・Akciju saraksts・Voyager Therapeutics Inc

Search

Voyager Therapeutics Inc

Slēgts

4.22 2.43

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.07

Max

4.33

Galvenie mērījumi
By Trading Economics
Ienākumi	466K -27M
Pārdošana	2M 15M
Peļņas marža	-178.834
Darbinieki	141
EBITDA	-2M -29M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+255.21% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	345K 229M
Iepriekšējā atvēršanas cena	1.79
Iepriekšējā slēgšanas cena	4.22

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. apr. 23:49 UTC

Galvenie ziņu notikumi

New Zealand 1Q Inflation Higher Than Expected

2026. g. 20. apr. 23:10 UTC

Karstas akcijas

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

2026. g. 20. apr. 22:53 UTC

Galvenie tirgus virzītāji

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment

2026. g. 20. apr. 23:45 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026. g. 20. apr. 23:44 UTC

Tirgus saruna

Gold Consolidates as End of Cease-Fire Looms -- Market Talk

2026. g. 20. apr. 23:39 UTC

Tirgus saruna

Rio Tinto Posts Strong Start to Year -- Market Talk

2026. g. 20. apr. 23:30 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. apr. 23:30 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 20. apr. 23:30 UTC

Tirgus saruna

Super Retail's Earnings Outlook Less Rosy -- Market Talk

2026. g. 20. apr. 23:09 UTC

Tirgus saruna

Viva Energy's Refinery Fire More Benign Than Jefferies Thought -- Market Talk

2026. g. 20. apr. 22:31 UTC

Iegādes, apvienošanās, pārņemšana

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

2026. g. 20. apr. 22:26 UTC

Iegādes, apvienošanās, pārņemšana

West African Resources Says Sanbrado, Toega Operations Not Subject to Govt Request for Additional Participation

2026. g. 20. apr. 22:25 UTC

Iegādes, apvienošanās, pārņemšana

West African Resources Plans to Distribute Cash Proceeds to Shareholders Via Special Dividend

2026. g. 20. apr. 22:25 UTC

Iegādes, apvienošanās, pārņemšana

West African Resources Aims for Acquisition to Be Completed by End-2026

2026. g. 20. apr. 22:25 UTC

Iegādes, apvienošanās, pārņemšana

West African Resources Says to Work Cooperatively With Govt to Finalize Deal Terms

2026. g. 20. apr. 22:25 UTC

Iegādes, apvienošanās, pārņemšana

West African Resources Says Acquisition Would Be for A$175 Million

2026. g. 20. apr. 22:24 UTC

Iegādes, apvienošanās, pārņemšana

West African Resources Says Burkina Faso Govt Issues Decree to Acquire 25% of Kiaka

2026. g. 20. apr. 22:15 UTC

Iegādes, apvienošanās, pārņemšana

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

2026. g. 20. apr. 22:01 UTC

Iegādes, apvienošanās, pārņemšana

Amazon Invests $5B in Anthropic Amid Expanded Collaboration

2026. g. 20. apr. 21:38 UTC

Tirgus saruna

Apple's New CEO Will Face Immediate Pressure on AI Strategy -- Market Talk

2026. g. 20. apr. 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Uber Expands Stake In Lucid for Robo-Taxis. This Is How Tesla's Stock Is Responding. -- Barrons.com

2026. g. 20. apr. 21:24 UTC

Tirgus saruna

Apple's CEO Change Timing Will Garner Mixed Reaction, Analyst Says -- Market Talk

2026. g. 20. apr. 21:24 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 20. apr. 21:13 UTC

Peļņas

Alaska Air: Expansion of Card Portfolio Expected to Accelerate Loyalty Platform Beyond Incremental $150M Profit Outlined in Alaska Accelerate Strategy

2026. g. 20. apr. 21:10 UTC

Peļņas

Alaska Air to Move Toward a Single Issuer for Atmos Rewards Credit Cards

2026. g. 20. apr. 21:09 UTC

Peļņas

Alaska Air Sees 2Q Capacity Up About 1% Year-Over-Year, Down Nearly a Point From Original Views, on 'Proactive Trimming' of May and June Capacity

2026. g. 20. apr. 21:08 UTC

Peļņas

Alaska Air 'Continues to Operate From a Position of Strength,' With Healthy Balance Sheet, Strong Liquidity, About $20B in Unencumbered Assets

2026. g. 20. apr. 21:07 UTC

Peļņas

Alaska Air: Taken Together, Rev, Cost and Fuel Assumptions Result in 2Q Adjusted Loss Per Share Estimate of About $1

2026. g. 20. apr. 21:05 UTC

Peļņas

Alaska Air: This Assumption Adds About $600M of Expense to 2Q, Equivalent to EPS Headwind of $3.60

2026. g. 20. apr. 21:05 UTC

Peļņas

Alaska Air Expects 2Q Fuel Cost to Average About $4.50 Based on Forward Curve Today

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

255.21% augšup

Prognoze 12 mēnešiem

Vidējais 14.67 USD 255.21%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

8

Pirkt

0

Turēt

0

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Citi krājumi no sektora

MDT

Medtronic PLC

85.26

A

Agilent Technologies Inc

120.85

VEEV

Veeva Systems Inc

168.97

HQY

HealthEquity Inc

86.11

NEOG

Neogen Corp

9.63

Live chat